Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$659.19M$659.19M+18.2% vs Q1 2023 Net Income-$91.64M-$91.64MN/M vs Q1 2023 EPS Diluted-$0.30-$0.30N/M vs Q1 2023 Gross Profit$238,060,000+33.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow-$4,410,000N/M Free Cash Flowderived-$13,608,000N/M Margins · derivedGross margin36.1%+4.2 pt vs Q1 2023
Operating margin-1.6%−7.8 pt vs Q1 2023
Net margin-13.9%−12.7 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end